Strong Merck stock trades near a 52-week high as cancer vaccine win lifts outlook

Merck & Co., Inc. (US58933Y1055) stock is trading close to a 52-week high in late August 2026 as investors respond to strong oncology data and resilient fundamentals, with shares recently quoted around $152.85 and a 52-week high of $154.49.

Recent market commentary dated August 24, 2026 highlighted that Merck shares opened at $152.43 in the latest New York Stock Exchange session, placing the stock very near that 52-week high of $154.49 and underscoring the strength of the recent move in the wake of positive melanoma vaccine data. A separate real-time quote snapshot on August 24, 2026 showed Merck trading at $152.85, a gain of 0.03 percent versus a previous close of $152.55, with the price range between the $77.58 one-year low and the $154.49 one-year high framing how far the shares have climbed over the past twelve months.

For investors, the number stands out: a market capitalization of $376.37 billion calculated at a share price of $152.55 as of August 24, 2026, highlighting how Merck has cemented itself among the largest global healthcare companies as its oncology franchise and broader pipeline support long-term growth expectations.

Oncology data drives latest rally

One of the most visible current catalysts for Merck stock is recent success in a personalized cancer vaccine program for high-risk melanoma patients, where the therapy is combined with the company’s immune checkpoint inhibitor Keytruda. Coverage dated August 24, 2026 summarized that Merck and a partner reported Phase 3 data showing improved recurrence-free survival and distant metastasis-free survival when the customized mRNA-based treatment was added to Keytruda, reinforcing confidence in Merck’s oncology growth engine and helping explain why the shares have been moving higher toward the top of their 52-week range.

Another report published August 24, 2026 noted that Merck stock jumped to a 52-week high of $154.49 in the prior trading week and gained more than 12 percent over that week, a move linked to the melanoma vaccine data and the perceived validation of the personalized mRNA cancer treatment platform. That same coverage pointed to a two-week streak of gains for Merck shares, suggesting that the market has been repricing the company’s long-term oncology opportunity in response to the trial win and the potential for expanded indications over time.

The scale of the recent reaction has been significant in market-value terms. A separate analysis dated August 24, 2026 described how Merck added $43 billion in equity value after the cancer vaccine trial win, with shares closing up 12.5 percent on the day the Phase 3 results were first highlighted, one of the biggest single-session moves in the company’s history. For shareholders, that single-day increase in market capitalization illustrates how central oncology has become to Merck’s valuation story.

Latest earnings and guidance context

Beyond the cancer catalyst, Merck’s most recent reported quarter provides further context for the current stock level. An earnings overview compiled on August 24, 2026 indicated that Merck last posted quarterly results on August 4, 2026, with revenue of $16.61 billion, ahead of a consensus forecast of $16.37 billion, and a reported earnings per share of negative $0.13, beating an expected loss of $0.26 per share. The quarter’s revenue was up 5.1 percent compared with the same quarter a year earlier, reflecting growth across key therapeutic areas even as the company absorbed higher research and development spending.

The same overview highlighted that Merck achieved a return on equity of 16.73 percent and maintained a net margin of 4.77 percent for that latest quarter. While the negative earnings per share figure reflects one-off items and heavy investment, the positive year-over-year revenue growth and double-digit return on equity show that the underlying business remains profitable and capable of funding its pipeline internally, an important signal given the capital intensity of late-stage clinical trials in oncology and vaccines.

Looking at the full-year picture, the earnings summary described Merck’s fiscal 2026 guidance for earnings per share in the range of $2.66 to $2.76. Sell-side forecasts embedded in that same dataset pointed to expected earnings per share of 2.76 for the current fiscal year, aligning with the upper end of management’s outlook. For investors, the alignment between guidance and consensus suggests that the market views Merck’s current trajectory as broadly credible, with upside potential tied to successful execution of oncology and vaccine programs and the management of upcoming patent expirations.

Analyst consensus and valuation signals

Several institutional-trading and analyst summaries dated August 24, 2026 pointed to a broadly constructive view on Merck stock. Across multiple reports, the shares were characterized as holding an average rating of Moderate Buy, with a consensus target price of $144.10. The fact that the current quote near $152 to $153 sits above that average target illustrates how the market has pushed the valuation beyond what the consensus had previously modeled, likely in response to the melanoma vaccine data and resilience in recent quarterly results.

At the same time, those same sources noted that while sentiment is positive overall, some analysts have flagged valuation and execution risks. Commentators referenced concerns about the 2028 patent expiration for Keytruda in major markets, a key event that could affect Merck’s earnings profile later in the decade. The quantified gap between the present share price around $152.85 and the consensus target of $144.10 underscores that the stock is now trading at a premium to the average analyst outlook, putting more pressure on Merck to deliver sustained clinical and commercial success to justify the higher valuation.

Another perspective in institutional-activity reports is that Merck’s one-year price range between $77.58 and $154.49 shows the scale of the turnaround in recent months. With the stock trading less than $2 below its 52-week high following a double-digit percentage gain in the prior week, investors appear to be focusing on near-term growth drivers such as the melanoma vaccine and upcoming data readouts, while keeping an eye on longer-term questions around patent cliffs and diversification beyond Keytruda.

Dividend and income profile

In addition to growth, Merck remains a dividend-paying company, an aspect that can matter for income-oriented investors. A dividend overview dated late August 2026 cited the company’s quarterly dividend of $0.85 per share, implying an annualized payment of $3.40 and a dividend yield of 2.2 percent based on the share price at the time of that snapshot. With the shares now trading near $152.85, that same $3.40 annual dividend would correspond to a yield modestly above 2 percent, providing a steady income stream alongside the capital appreciation that has accompanied the oncology news.

The dividend timing outlined in the same dataset indicated that Merck’s quarterly payout is scheduled for early October 2026, with a record date in mid-September and an ex-dividend date on September 15, 2026. For investors planning around cash flows, these concrete dates offer clarity on when dividend income will be recorded and paid, and they reinforce Merck’s pattern of regular shareholder returns even as the company invests heavily in clinical programs.

Combining the dividend profile with the earnings guidance gives a more complete picture of Merck’s financial strategy. With fiscal 2026 earnings per share targeted between $2.66 and $2.76 and an annual dividend of $3.40 per share, Merck is effectively returning more in cash dividends than its current-year earnings forecast, a choice that underscores management’s confidence in future profit growth beyond 2026 and its willingness to maintain shareholder distributions through periods of elevated research and development spending.

Institutional flows and technical backdrop

Multiple filings and portfolio updates released on August 24, 2026 detailed changes in institutional holdings of Merck stock. These noted that various asset managers had either increased or decreased their positions, but the consistent pricing reference of $152.43 as the opening level in the latest session reinforced the picture of a stock trading in a tight band near its recent highs. The technical backdrop described in these pieces pointed to a 50-day moving average around $128.09 and a 200-day moving average close to $121.29, illustrating that the current price near $152.85 sits well above both key trend indicators.

From a chart perspective, the fact that Merck shares are trading more than $24 above the 50-day moving average and more than $31 above the 200-day moving average signals a strong uptrend. This distance to the moving averages also highlights that recent gains, including the more than 12 percent advance in the prior week, have moved the stock into a technically extended zone where some investors may choose to lock in profits, while momentum-oriented traders might see further upside if new positive data or guidance emerges.

Intraday performance snapshots from August 24, 2026 showed that despite the earlier surge, the stock was only moving modestly on the day, with a 0.03 percent gain from the previous close of $152.55 to $152.85. That small change, compared to the prior double-digit percentage move tied to the cancer vaccine news, suggests that the market is digesting the new information and reassessing valuation levels rather than continuing the steep rally at the same pace.

Keytruda and the oncology franchise

Keytruda, Merck’s blockbuster immunotherapy, remains central to the company’s growth story and to the recent focus on the melanoma vaccine trial. The combination regimen in high-risk melanoma leverages Keytruda’s role in unleashing the immune system against cancer cells while the personalized mRNA vaccine trains the immune system to recognize tumor-specific antigens. The reported improvement in recurrence-free and distant metastasis-free survival in the Phase 3 trial indicates that this dual approach may offer a meaningful clinical benefit over Keytruda alone, reinforcing Merck’s competitive position in oncology.

The stakes are high. Patent expirations for Keytruda expected in 2028 in several major jurisdictions mean that Merck needs new growth drivers to offset potential future revenue erosion. The quantified market reaction, including the $43 billion increase in market value and the 12.5 percent single-day share price jump following the melanoma data, shows that investors see the personalized vaccine program as one such driver, potentially expanding the reach of Keytruda-based regimens and creating new revenue streams even as the original patent protection winds down.

Beyond melanoma, Merck’s oncology portfolio includes multiple indications for Keytruda across lung cancer, head and neck cancer, and other tumor types, as well as other pipeline candidates. While specific revenue figures by product in the latest quarter are not detailed in the available summaries, the overall 5.1 percent year-over-year revenue growth in the August 4, 2026 quarter suggests that oncology, together with vaccines and other therapeutic areas, continues to contribute to the top line in a meaningful way.

Representative product: Keytruda in melanoma

Within Merck’s broader business, Keytruda is a representative product that illustrates the company’s strategy in oncology and its current catalyst. In high-risk melanoma, the drug has been used as adjuvant therapy to reduce the risk of recurrence after surgery, and the recent trial pairing Keytruda with a personalized mRNA cancer vaccine aims to further reduce recurrence and improve long-term outcomes. The reported Phase 3 results demonstrating improved recurrence-free and distant metastasis-free survival when the combination is used suggest that Keytruda’s role in melanoma may evolve from a single agent to a backbone therapy in combination regimens.

For Merck, the success of Keytruda in melanoma goes beyond one indication. It supports a broader narrative that immuno-oncology treatments, particularly when combined with targeted or personalized therapies, can deliver substantial clinical benefits. That narrative underpins not only Merck’s current valuation but also its willingness to invest heavily in research and development, as reflected in the latest quarter’s negative earnings per share driven by higher R&D spending despite growing revenue.

Merck stock and current trading level

As of August 24, 2026, a real-time quote snapshot showed Merck & Co., Inc. common stock trading on the New York Stock Exchange at $152.85, reflecting a 0.03 percent increase from a prior closing price of $152.55 and confirming the stock’s position close to its 52-week high of $154.49. That trading level, combined with a market capitalization of $376.37 billion calculated at $152.55 per share earlier in the day, positions Merck among the largest healthcare companies globally and indicates that the market is pricing in substantial long-term value from its oncology and vaccine programs.

For retail investors, the current configuration of Merck stock integrates several key elements: a share price that has risen from a one-year low of $77.58 to within a few dollars of a 52-week high of $154.49, a recent quarter with revenue of $16.61 billion and 5.1 percent year-over-year growth, earnings guidance for fiscal 2026 in the $2.66 to $2.76 per share range, and an annual dividend of $3.40 per share that equates to a yield just above 2 percent at current prices. Together, these figures capture why Merck stock is drawing attention in late August 2026 as a large-cap healthcare name combining growth, income, and a high-profile oncology catalyst.

Read more

TheStreet coverage of Merck cancer vaccine trial win

Fact box

Company: Merck & Co., Inc.

ISIN: US58933Y1055

Ticker: MRK

Exchange: New York Stock Exchange

Price (as of August 24, 2026, 11:11 a.m. ET): $152.85 USD

Market cap: $376.37 billion (as of August 24, 2026)

Sector / Industry: Health Care / Pharmaceuticals

Index membership: S&P 500